Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Participants in clinic trial went from being unable to get out of bed to being productive and interacting with loved ones ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

Launched this year, Miami-based Hope Therapeutics is a developer of NRX-100, a ketamine drug used to treat suicidal ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...

Vagus nerve stimulation (VNS) shows a positive treatment effect and improved quality of life (QoL) among patients with ...

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, ...